A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Alcon Research81 enrolled

Overview

The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Open-angle Glaucoma Ocular Hypertension

Interventions

Travoprost 0.004%/timolol 0.5% ophthalmic solutionDRUG

One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid

Travoprost ophthalmic solution, 0.004%DRUG

One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid

Timolol maleate ophthalmic solution, 0.5%DRUG

One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients with open-angle glaucoma or ocular hypertension; * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Visual acuity worse than 0.60; * Other protocol-defined exclusion criteria may apply.

Locations (1)

Seattle

Seattle, Washington, United States

Outcomes

Primary Outcomes

Patient compliance

Patient compliance will be measured with a dosing aid that records time and date of study drug administration

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.